Law Professor & Assoc. Dean @URLawSchool; mom & trail hiker/runner; loves strong patent rights, legal interpretation, and good red wine

Joined November 2013
50 Photos and videos
Kristen Osenga retweeted
Last week, the Supreme Court ruled in Hikma v. Amarin. Before the decision, Kristina Acri broke down the questions at the center of the case -- and explained why the ruling "could have a dramatic effect on incentives to invest in researching additional uses for FDA‑approved medicines." Read her analysis in @dcexaminer: buff.ly/x57IBM4
4
4
146
Excellent new papers from @IPPolicyInst scholars about “patent thicket” and “evergreening” claims. The collection offers an important, evidence-based look at how post-approval innovation, patent timing, and generic competition actually work in practice. unpackingip.org/ipandbiophar…
26
"Effective drug pricing policy should be based on empirical evidence — not unsupported patent narratives." Great new one-pager by @AdamMossoff on why strong patent rights are essential to research, investment, and innovation that improve and save lives: static1.squarespace.com/stat…

1
2
157
Kristen Osenga retweeted
🎙️ Check out this episode of the IP Protection Matters podcast featuring insights from @ProfKOsenga, Associate Dean for Academic Affairs at the University of Richmond School of Law. She discusses the link between IP and innovation, patent eligibility, so-called patent "evergreening," and more. ipprotectionmatters.org/epis…
1
2
101
Had a great conversation last week with @PatentGene at the @IPWatchdog Unleashed podcast. We talked about patents, IP policy, the dangers of mandatory "royalty-free" licensing -- and my career path! Listen here: youtube.com/watch?v=UiDm-zVs…
46
"When the general public hears 'royalty-free,' the focus is on the word 'free.' But there's no such thing as a free lunch." Great to speak to @mlexclusive about the threat that mandatory "royalty-free" licensing models pose to innovation. Read more here: mlex.com/mlex/antitrust/arti…
50
Kristen Osenga retweeted
"Efficient infringement" works only when innovators lack the resources to fight back. It's why third-party litigation funding is so integral to leveling the playing field. Listen to @ProfKOsenga on @Clause8Podcast: voiceofip.com/p/the-hidden-c…
3
2
122
I enjoyed chatting with @EliMazour for @Clause8Podcast about the threats that mandatory "royalty-free" licensing models -- like those promoted by Big Tech's "Alliance for Open Media" -- pose to innovation in streaming technology. Listen here: voiceofip.com/p/the-hidden-c…
2
2
78
Kristen Osenga retweeted
Thank you to @ProfKOsenga of @URLawSchool for joining @georgemasonlaw and @masonlec to present her #FormationStage paper to #ScaliaLaw students and faculty: 📑"Who's Suing Whom? Patent Litigant Characteristics & the Prevailing Patent Enforcement Narratives" The #RibsteinWorkshop honors the legacy of academic pioneer Larry Ribstein and his commitment to #NewScholarship.
4
4
466
Kristen Osenga retweeted
Patents only function as property rights if they can be enforced. Without enforcement, they're just paper promises to millions of American inventors.
1
1
69
The U.S. innovation economy depends on enforceable IP rights and a legal system that offers meaningful access to justice. The Protecting Third Party Litigation Funding From Abuse Act deters investment and discourages innovation. My latest in @TheWellNews: thewellnews.com/opinions/a-m…
1
2
113
Kristen Osenga retweeted
For months, critics have claimed third-party litigation funding invites foreign interference in U.S. courts. The facts say otherwise. We show that existing safeguards work and American inventors and national security are not at risk. inventorsdefense.org/wp-cont…

2
2
70
Kristen Osenga retweeted
Innovation only thrives when creators have the tools to defend what they build.
1
1
74
Kristen Osenga retweeted
Litigation funding lets small inventors stand up to deep-pocketed infringers like Google, Samsung, and Apple. Congress needs to strengthen that lifeline -- not eliminate it. Read more from @ProfKOsenga below: news.bloomberglaw.com/legal-…
2
1
83
My latest op-ed: "There’s nothing inherently sinister about third-party support in litigation. ... It’s about access to justice -- ensuring that the strength of your idea matters more than the size of your legal budget." realclearpolicy.com/articles…
1
70
Kristen Osenga retweeted
This is false. PERA would simply restore patent protection for real medical and biotech innovations while keeping strict limits in place. For instance, it does not allow patents on genes, natural phenomena, or basic science. But it would ensure that new tests, treatments, and life-saving technologies can be protected. Get the facts on PERA: c4ip.org/tag/pera/
1
2
78